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ABSTRACT 
 
Cis-regulatory variants that alter gene expression can modify disease risk, onset, and 
severity, but none have previously been identified in Huntington Disease (HD). Here we 
provide in vivo evidence in HD patients that cis-regulatory variants in the HTT promoter 
are bidirectional modifiers of HD age of onset. HTT promoter analysis identified an NF- 
B binding site regulating HTT promoter transcriptional activity. A non-coding SNP, 
(rs13102260:G>A), within this binding site impaired NF-B binding, reduced HTT 
transcriptional activity and HTT protein expression. Presence of the rs13102260 minor 
(A) variant on the HD disease allele was associated with delayed age of onset in familial 
cases, while presence of the rs13102260 (A) variant on the wild-type HTT allele was 
associated with earlier age of onset in HD patients in an extreme case based cohort. Our 
findings provide a novel mechanism linking allele-specific effects of rs13102260 on HTT 
expression to HD age of onset, and have significant implications for HTT silencing 
treatments in development. 
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Huntington Disease (HD) is an autosomal dominant neurodegenerative disease caused by 
a polyglutamine-encoding CAG repeat expansion in exon 1 of the huntingtin gene (HTT). 
While huntingtin is ubiquitously expressed in most tissues
1,2
, the neuropathology of HD  
is characterized by relatively selective neuronal cell death in the striatum and cortex
3
. 
Wild-type huntingtin plays a crucial role in development of the nervous system and is 
protective against various forms of cytotoxicity, including neurotoxicity induced by 
mutant huntingtin
4,5
. The cytotoxicity of mutant huntingtin has been proposed to be the 
result of several mechanisms, including the disruption of axonal transport, mitochondrial 
dysfunction, imbalance in calcium homeostasis and excitotoxicity, altered proteolysis, 
impairment of the ubiquitin proteasome system and altered transcription
6
. The balance of 
expression between mutant and wild-type huntingtin may be an important modulator of 
pathogenesis and disease progression in HD. 
In HD, the length of the CAG repeat in the expanded HTT disease allele inversely 
correlates with age of onset (AO). Although CAG repeat length accounts for a large 
proportion of the variation in AO
7
, there is significant variability observed between 
expected and observed AO in HD patients
8
. HD patients with identical CAG repeat 
 
lengths, particularly those with CAG sizes between 40-44, can have AOs that differ by 
more than 20 years
9
. Increasingly, disease-associated non-coding single-nucleotide 
polymorphisms (SNPs) are being identified as potential modifiers of disease 
progression
10,11
. Cis-acting regulatory SNPs (rSNP) can alter the binding affinity of 
transcription factors to their binding sites, changing gene transcriptional activity and 
consequently modifying disease phenotype or progression. Other modifiers such as 
interacting genes and environmental factors likely also contribute to the variation in AO 
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observed in HD
12
. Both cis- and trans-acting factors that regulate HTT gene expression 
are likely to affect AO and disease progression in HD. 
Genetic variation in regulatory sequences can affect the binding of transcription 
factors (TF) and alter the rate of transcription; such regulatory sequence variations could 
affect the expression of the HTT gene leading to functional consequences in HD. The 
expression levels of both wildtype and mutant huntingtin have been shown to modify the 
disease phenotype in many HD models
13-16
. The partially characterized murine Htt and 
human HTT promoters have a high GC content and contain a number of consensus 
binding sites for known TFs such as Sp1, AP2 and p53
17-20
. 
To determine whether genetic variation in the human HTT promoter influences 
the transcriptional rate of HTT, we established a panel of HTT promoter reporter 
constructs originating from HD patients We identified a NF-B binding site containing a 
human SNP (rs13102260:G>A) that modulated the binding of NF-B, resulting in 
reduced transcriptional activity of the HTT promoter in reporter gene assays. In order to 
investigate this SNP for disease-modifying effects, we assessed HD patient cohorts. We 
applied family-based designs and extreme phenotype sampling (EPS) using case 
extremes to increase efficiency in testing this candidate SNP for effects on HD age of 
onset
21-26
. As we show here, familial case and EPS based designs compared to random 
 
sampling, provided more powerful strategies for testing low frequency variant effects by 
enriching for genetic effects. In familial cases, we observed that the minor (A) sequence 
variant phased to the HD disease allele was associated with delayed age of onset as 
compared to the (G) sequence variant. In contrast, in our EPS cohort, we found that the 
(A) variant associated with an earlier AO when phased to the wild-type allele. Finally, we 
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showed that the genotype at rs13102260 regulates HTT protein levels correlating with the 
observed SNP effects on HD age of onset. In this study we provide in vivo evidence that 
cis-regulatory variants in the HTT promoter region can act as bidirectional modifiers 
influencing age of onset in HD with allele-specific effects, and that this effect was 
predicted by our in vitro data showing the direct effect of rs13102260 on NF-B binding 
and huntingtin expression.  
 
RESULTS 
 
 
Cis-acting variants alter transcriptional activity of the human HTT promoter 
 
Genomic regulatory sequences and binding motifs play key roles in transcriptional 
regulation. Genetic variants within TFBS might affect the binding of TFs and subsequent 
up- or down-regulation of transcription. Recent studies suggest that transcription rate 
data is more informative than steady-state mRNA abundance to use in gene regulation 
analysis
27
. We engineered a panel of constructs to study the transcriptional activity of the 
human HTT promoter using the luciferase reporter system. DNA samples from four 
representative HD patient haplotypes were selected (Supplemental Data 1). The human 
HTT promoter from the YAC128 transgenic mouse model of HD was also cloned and 
included in the panel. This transgenic mouse carries the entire human HTT promoter and 
gene with an expanded CAG repeat inserted into a yeast artificial chromosome
28
. Twelve 
distinct HTT promoter constructs were generated, including the eight alleles from the four 
HD patients, three pseudo-alleles with random PCR-induced sequence variants, and one 
from the YAC mouse. Basal transcriptional activity of the twelve constructs was initially 
measured using the luciferase reporter system in a human embryonic kidney cell line 
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(HEK293A). Eleven constructs displayed similar levels of basal transcriptional activity, 
while construct 5 (a pseudo-allele) exhibited a significant reduction in transcriptional 
activity compared to the other constructs (t(10)=4.32, P<0.01) (Fig. 1a). Similar 
experiments were performed in the ST14A cell line, a conditionally immortalized rat 
striatal cell line displaying similarities to striatal medium spiny neurons
29,30
, with 
comparable results (t(10)=5.83, P<0.001) (Fig. 1b). The transcriptional activity of 
construct 5 was significantly reduced compared to the parental construct 4 
(approximately 50%) in both the HEK293A and the ST14A cells. We next sequenced the 
3.7 kb HTT promoter region for all twelve constructs (data not shown). Sequence 
comparison between constructs 4 and 5 identified ten sequence differences in the non- 
coding region of the huntingtin promoter (Fig. 1c). 
 
Reduced transcriptional activity by the proximal HTT promoter region 
 
We used a modified form of the RAVEN (Regulatory Analysis of Variation in 
ENhancers) bioinformatics software
31 
(http://www.cisreg.ca/RAVEN) to identify putative 
TFBS affected by the identified sequence variants. Our results prompted an investigation 
of known human SNPs overlapping the identified binding sites. Four human SNPs that 
overlap with the putative TFBS in this region were identified: rs35207696, rs28441493, 
rs184840072 and rs13102260 (Fig. 1c). rs35207696, rs28441493, and rs184840072 are 
rare genetic variations with no individual genotype data and no frequency submission 
(http://www.ncbi.nlm.nih.gov). In contrast, the rs13102260 (G>A) occurs in the human 
population with a minor allele frequency MAF (A)=0.158/792 (1000 Genomes Project 
Phase 3); (MAF) of 0.042 for CEU (Caucasian European); MAF=0.050 for CHB+JPT 
(Han Chinese; Japanese) and MAF=0.441 for YRI (African Yoruban) 
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(http://www.ncbi.nlm.nih.gov). As the constructs 4 and 5 differed in several loci 
 
throughout the promoter region, a sequence-swapping procedure was used to identify the 
segment in the promoter of construct 5 responsible for the reduced reporter expression 
shown in Figure 1a and 1b. The 3.7 kb promoter was divided into three consecutive 
promoter fragments, A, B and C, with fragment C immediately proximal to the HTT 
translation initiation codon (Fig. 1c). Each promoter fragment was sequentially swapped 
between construct 5 and construct 4. Swapping the most distal A and B fragments did not 
alter the baseline transcriptional activity of construct 4 (Fig. 1d). However, when swapped 
from construct 5 to 4, fragment C significantly reduced the transcriptional activit              
y of construct 4 to the level of construct 5. In contrast, swapping fragment C from 
construct 4 into construct 5 conferred normal reporter expression, rescuing the reduced 
baseline transcriptional activity of construct 5 (F(5,12)=11.9, P<0.001, ANOVA with 
Bonferroni’s multiple comparison test). We next assessed if fragment C required the distal 
A and B fragments to be present in order to have this modulatory effect on        
expression. Isolated fragment C from both constructs 4 and 5 showed similar levels of 
transcriptional activity as the full-length constructs they originated from (F(3,8)=41.0, 
P<0.001, ANOVA with Dunnett’s multiple comparison test) (Fig. 1e). From these results 
we concluded that the proximal promoter region of fragment C (~1.1kb) contains cis- 
expression QTL (eQTL) that regulate gene expression, and that construct 5 contains 
genetic variation in this region that significantly reduces HTT expression. 
 
Cis-regulatory SNP in NF-B binding site reduces transcriptional activity 
 
The alignment between constructs 4 and 5 revealed only three sequence variants in the 
identified eQTL in the 1.1 kb proximal HTT promoter region. In silico analysis further 
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predicted these variants to overlap with binding sites for CF1/USP, AML-1 and NF-B 
(Fig. 1c). The predicted TFBS, the sequence variant position relative to the translation 
initiation codon start site, and the sequence variants for constructs 4 and 5 were, 
respectively: CF1/USP, -763 (T/C); AML-1, -392 (A/G); and NF-B, -139 (G/T) (Fig. 
1c). We next investigated the functional significance of altered binding of the identified 
TFs on transcriptional regulation of the HTT promoter. We performed site-directed 
mutagenesis to introduce the three identified construct 5 sequence variants into construct 
4. The resulting promoter constructs revealed that changes at the predicted CF1/USP and 
the AML-1 binding sites did not affect the transcriptional activity in the reporter assay 
(Fig. 1f). In contrast, the construct 5 variant of the NF-B binding motif significantly 
decreased the transcriptional activity of construct 4C to the levels observed for the 
construct 5 full-length and fragment C constructs (F(4,23)=43.6, P<0.001, ANOVA with 
Dunnett’s multiple comparison test). The single base pair difference in the NF-B binding 
sites of promoter constructs 4 and 5 was in the tenth and last nucleotide of the T          
FBS (Fig. 1g). These results suggested that the construct 5 variant of the NF-B binding 
site caused the reduction in transcriptional activity. 
We located the rs13102260 (G>A) at the first base position of the NFκB TFBS 
consensus motif from our database search on SNPs overlapping the identified putative 
TFBS in the HTT promoter region (Fig. 1g). We thus identified a human SNP that was 
present in the same NF-B binding site, but that was distinct from the nucleotide variation 
that we had originally investigated in vitro. Site-directed mutagenesis was           
performed to introduce the rs13102260 variant into construct 4C in order to study its 
effect on transcriptional activity. The rs13102260 (A) variant caused an approximate 50% 
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reduction in transcriptional activity similar to constructs 5 and 5C (F(5,14)=26.2, 
P<0.001, ANOVA with Dunnett’s multiple comparison test) (Fig. 1h). Thus sequence 
changes at both the first and last position of the NF-B binding site resulted in significant 
reduction in transcriptional activity of the HTT promoter. 
 
Activated NF-B binds to the HTT promoter in vitro and in vivo 
 
We next performed a series of biochemical experiments to determine the binding 
characteristics of the identified TFs and to functionally validate NF-B binding to the 
HTT promoter in vitro and in vivo. We performed chromatin immunoprecipitation (ChIP) 
analysis to study the putative NF-B occupancy of the huntingtin promoter. Enrichment 
of NF-B binding to the predicted TFBS was assessed using quantitative real-time PCR 
(qPCR). To investigate whether NF-B bound the site in vivo, we first performed ChIP 
using different brain regions of naïve mice (Fig. 2a-c). The mouse Htt promoter contains 
three putative NF-B TFBS within 1000 bp upstream of the translation initiation codon 
(Supplementary Fig.1a). There was a clear NF-B enrichment in all brain regions and at 
all analyzed TFBS regions comparable to what was observed for the IL6 promoter 
(positive control for NF-B binding) (striatum F(7,32)=1.75, P=0.134; pre-frontal cortex 
F(7,32)=2.44, P<0.05; cerebellum F(7,32)=7.22, P<0.001, one-way ANOVA). 
Interestingly, there was a significantly higher level of NF-B recruitment in striatum 
compared to pre-frontal cortex and cerebellum at TFBS2 (Tissue F(2,96)=5.53, P<0.01; 
TFBS F(7,96)=3.15, P<0.01; interaction F(14,96)=1.17, P=0.311, two-way ANOVA) 
(Fig. 2d). The similar level of enrichment at each TFBS is likely due to limited ChIP 
resolution (200-1000bp). To study the NF-B occupancy on the HTT promoter in a 
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human context, ChIP analysis was performed in lymphoblastoid cell lines (LCL) derived 
from HD patients (Supplementary Fig. 1b). There was an increased enrichment of NF-B 
at the single predicted NF-B TFBS (comprising rs13102260) in human LCLs 
(F(3,32)=4.28, P<0.05, one-way ANOVA with Dunnett’s multiple comparison test) 
compared to a region upstream in the HTT promoter region that we used as a control 
containing two putative NF-B TFBS (-2065; -2011bp from translation start site) (Fig. 
2e). Rat striatal ST14A cells, which is the system employed in the reporter assays, were 
then stimulated with TNFα to activate the NF-B pathway. The rat Htt promoter contains 
four putative NF-B TFBS within 1000 bp upstream of the translation initiation codon 
(Supplementary Fig.1c). We assessed the binding of NF-B to the distinct TFBS using 
three different primer sets. We observed an enrichment of NF-B for all three regions 
comparable to the IL6 promoter (F(7,16)=5.09, P<0.01, one-way ANOVA with 
Bonferroni’s multiple comparison test) (Fig. 2f). These results thus demonstrate an 
enrichment of NF-B occupancy at the predicted NF-B TFBS proximal to the TSS both 
in vitro in immortalized rat striatal ST14A cells and in LCLs derived from HD patients, 
as well as in vivo in mouse striatum, pre-frontal cortex and cerebellum. Notably, we 
observed a significantly higher level of NF-B recruitment in striatum compared to pre- 
frontal cortex and cerebellum. 
 
rSNP alters NF-B binding to the HTT promoter 
 
As shown in figure 1, sequence variants at both the first and the last position of the NF- 
B binding site resulted in significant reduction in transcriptional activity of the HTT 
promoter. We used electrophoretic mobility shift assays (EMSA) to more precisely 
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investigate the interactions between NF-B and the binding site harboring the rSNP. NF- 
B is predominantly cytoplasmic under normal conditions, but migrates to the nucleus 
upon activation by cytokines such as TNFα. We therefore performed TNFα stimulations 
to activate the NF-B pathway in ST14A cells prior to nuclear extract preparation. In the 
EMSA, NF-B bound more strongly to the allele 4 compared to the allele 5 
oligonucleotide in a concentration-dependent manner (Fig. 3a). The shifted band was 
abolished upon addition of unlabeled competitor oligonucleotide. The oligonucleotides 
(allele 5 oligonucleotide in particular) containing the NF-B binding site were prone to 
create secondary structures such as self-dimers or hairpin structures. The NF-B protein, 
however, also exhibited a high affinity to these secondary structures as well as to the 
duplexed oligonucleotide (data not shown). In the presence of recombinant human NF- 
B p50 protein, a single shifted band was observed that increased in intensity in a 
concentration-dependent manner (Fig. 3b). Addition of 0.9 gel shift units (gsu) produced 
a single band that was stronger for the allele 4 oligonucleotide than was observed for the 
allele 5 oligonucleotide. The allele 5 band was out-competed more efficiently with 
unlabeled competitor oligonucleotide, indicating lower binding affinity to the allele 5 
compared to the allele 4 oligonucleotide. EMSA confirmed that NF-B binding to the 
oligonucleotide containing the rs13102260 (A) variant was fully abolished, as assessed 
with both ST14A nuclear extract (Fig. 3c) and recombinant NF-B p50 protein (Fig. 3d). 
The binding of CF1/USP and AML-1 to the allele 4 and allele 5 target sequences was 
also assessed following incubation with ST14A nuclear extract. None of these showed 
decreased binding to the allele 5 target sequence (Supplementary Fig. 2). The p50/p65 
heterodimer is the most abundant of the NF-B dimers, displaying a very potent gene 
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regulatory function. Different DNA targets determine the final conformation of the 
heterodimer
32,33
. The p50/p65 dimer complex specifically recognizes the 5’- 
GGGRNYYYCC-3’ (R=unspecified purine; N=any nucleotide; Y= unspecified 
pyrimidine). The p50 subunit strictly recognizes 5’-GGGRN-3’, while the p65 subunit 
recognizes 5’-YYCC-3’, but at less stringency. These results suggest that the p50/p65 
heterodimer still binds to both the construct 4 and 5 variant at the tenth base position in 
the NF-B TFBS, but to a lesser extent due to reduced binding of the p65 subunit. In 
contrast, the rs13102260 (A) variant at the first position in the NF-B TFBS affects the 
binding of the p50/p65 heterodimer to a higher degree by abolishing the p50 binding to 
the HTT promoter. These findings demonstrate that sequence variants at the first as well 
as last base pair of the NF-B binding motif in the HTT promoter alter NF-B binding, 
subsequently reducing transcriptional activity of the HTT gene. 
 
Targeting of NF-B modulates HTT expression 
 
We next investigated whether the NF-B-mediated transcriptional activity on the HTT 
promoter was dynamic and therefore a potential therapeutic target. We first assessed 
whether siRNA knockdown of NF-B influenced HTT gene expression. This experiment 
showed that down-regulation of NFKB1 (specific for p105, precursor to the p50 subunit) 
and p65 mRNA levels, both of which encode critical components of the potent 
heterodimer p50/p65 complex, decreased the levels of HTT expression (t(6)=3.52, 
P<0.01) (Fig. 4a). The knockdown of NF-B was also associated with decreased p53 
mRNA to levels comparable with the decrease in HTT expression, p53 being an 
established NF-B target (t(6)=3.46, P<0.01, Supplementary Fig. 3a). We next stimulated 
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ST14A cells with TNFα to assess if the treatment would increase the transcriptional 
activity of the HTT promoter constructs. Upon TNFα-stimulation, construct 4 exhibited 
increased transcriptional activity (F(3,8)=29.7, P<0.001, one-way ANOVA with 
Dunnett’s test), in contrast to construct 5 that exhibited no change in expression 
compared to the untreated control (Fig. 4b). Caffeic acid phenethyl ester (CAPE), an 
active component of propolis from honeybee hives, is known for its anti-mitogenic, - 
carcinogenic, -inflammatory and immuno-modulatory properties
34
. CAPE blocks TNFα- 
induced activation of NF-B in a dose and time-dependent manner by preventing the 
translocation of the p65 subunit to the nucleus and by selectively inhibiting NF-B 
binding to DNA
35
. Stimulation of ST14A cells expressing construct 4 with TNFα in 
combination with CAPE treatment resulted in reduced transcriptional activity of the 
promoter in a CAPE dose-dependent manner (F(4,7)=6.24, P<0.05, one-way ANOVA 
with Dunnett’s test) (Fig. 4c). We next assessed the effects of CAPE treatment on the 
basal transcriptional activity of the HTT promoter constructs. Neither constructs 4 nor 5 
displayed changes in transcriptional activity levels when the ST14A cells were treated 
with CAPE in the absence of a NF-B-pathway activating treatment (Supplementary Fig. 
3b). Western blot analysis was performed to confirm a TNFα-induced increase in nuclear 
levels of NF-B protein in our experimental setting. TNFα-stimulated ST14A cell 
nuclear extract expressed all NF-B subunits, with the most dramatic increase in the p50 
subunit compared to untreated cells (Fig. 4d). The cytoplasmic fraction showed strong 
bands for the precursor subunits p100/p105, in addition to bands for the p50 subunit. 
There were, however, no bands for the p65, RelB and c-Rel subunits in the cytoplasmic 
fraction. Western blot analysis revealed that CAPE treatment did not affect the nuclear 
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p65 protein levels in the ST14A cells (Fig. 4d). Our results thus suggest that CAPE 
inhibits NF-B nuclear activity, perhaps through prevention of p65 binding to the HTT 
promoter. In summary, our results showed that siRNA knockdown of NF-B, TNFα and 
CAPE stimulations modulated the transcriptional activity of the HTT promoter. 
 
rs13102260 (A) variant on the HD disease allele is protective and associated with 
delayed age of onset 
Based on our in vitro findings we next studied the disease-modulatory effects of the 
rs13102260 (A) variant in HD patients. We previously showed that a specific HD 
haplotype was associated with later AO in Danish HD families
36
. Here we genotyped the 
familial cases to determine if the rs13102260 genotype was associated with delayed age 
of motor onset. We performed direct sequencing of HD subjects (n=98) originating from 
36 Danish HD families representing seven different haplotypes including the one 
associated with later AO. Direct sequencing revealed that all HD subjects with the 
haplotype that we previously showed to associate with later AO (B-haplotype), 
exclusively carried the rs13102260 (A) variant. Phasing of the (G) and (A) sequence 
variants was done in each HD family by segregation of affected and/or unaffected 
genotypes within the pedigree. We found that the (A) variant phased to the HD disease 
allele in all B-haplotype families (n=8). The other HD haplotypes that were not associated 
with later AO carried the (G) variant. We next performed association testing to further 
evaluate and quantify the effect of the rs13102260 (G/A) on AO in these HD        
patients. We restricted our analysis to HD subjects with a CAG-length of 41-55,  
including 35 (G/A) heterozygotes with the (A) phased to the HD disease allele, 41 
patients that were (G/G) homozygotes and six (A/A) homozygotes at rs13102260 (n=82) 
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(Supplementary Table 1). Analysis was performed using weighted least square models 
predicting observed ages of onset as a function of the (G/A) rs13102260 genotype, and 
expected age of onset based on the CAG repeat length as estimated by Langbehn et al
8
. 
Presence of the rs13102260 (A) variant on the HD disease allele had a clear association 
with age of HD onset, after first adjusting for expected age of onset based on CAG repeat 
length (Fig. 5a). The resulting mean delay of age of onset was 9.3 years for (A/G) 
heterozygotes at the mean expected age of onset in the data (40.1 years) compared to 
(G/G) homozygotes (t=5.08, 27.1 df, P<0.0001). The overall rSNP effect (main effect 
plus interaction) was statistically significant at P<0.0001 (F=14.40, df=2, 34.7). There 
was evidence for interaction between rs13102260 and the CAG-based expected age of 
onset (F=5.80, df= 1, 73.9, P=0.019) with the protective effect being stronger at lower 
CAG lengths (Fig. 5a, Supplementary Fig. 6). There was however no evidence of 
association in homozygous rs13102260 (A/A) individuals (adjusted mean difference: 
 
5.56 years, t=1.90, df=53.4, P=0.063) (n=6). Hence, our results showed that the 
rs13102260 (A) variant had a protective role and associated with delayed AO when 
phased to the HD disease allele. 
 
rs13102260 (A) variant on the wild-type allele associated with earlier HD age of 
onset 
We next genotyped an additional cohort of HD patients (UBC HD Biobank) in an effort 
to validate the observed disease-modulatory effects of the rs13102260 (A) variant on HD 
age of onset. We used a family-based design to collect the HD subjects. The patients 
included in this cohort were assessed individually for age of motor onset, in addition to 
being mapped into family pedigrees. We further applied an extreme phenotype sampling 
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approach in which we selected the most extreme subject from each pedigree i.e. on the 
basis of age of onset where the ratio between observed age of onset and expected (based 
on CAG-length)
8,37 
was used to identify early, mean or late age of onset HD subjects (see 
material and methods). This selection of case extremes, similarly to familial cases, 
enriches for alleles that contribute to disease, allowing detection of genotype associations 
in modest sample sizes. A total number of 459 HD subjects were genotyped for the 
rs13102260, of which only 28 out of 459 (approx. 6%, corresponding to MAF in 
Caucasians) were (G/A) heterozygotes, while the remainder where (G/G) homozygotes. 
We then genotyped relatives of the probands that were identified as (G/A) heterozygotes 
to phase the (A) variant to the wild-type or the HD disease allele. The rs13102260 (A) 
variant was almost exclusively 1) on the wild-type allele and thus 2) inherited from the 
unaffected parent (except for two subjects with the (A) variant phased to the HD disease 
allele) (Supplementary Table 2). As for the Danish cohort, we restricted our analysis to 
HD subjects with a CAG-length of 41-55, including 22 (G/A) heterozygotes with the (A) 
variant phased to the wild-type allele and 391 patients that were (G/G) homozygotes 
(n=413) (Supplementary Table 3). Analysis was performed using similar weighted least 
square models as for the Danish cohort. Presence of the rs13102260 (A) variant on the 
wild-type allele associated with age of HD onset, where subjects carrying the rs13102260 
 
(A) variant displayed on average an age of onset 3.88 years earlier than those with the 
rs13102260 (G) variant (t=-2.57, df=367, P=0.010) (Fig. 5a). There was no evidence for 
interaction between the rs13102260 and the CAG-based expected age of onset. In 
addition, given that the UBC data were collected on the basis of age of onset, with the 
SNP genotype as the unknown variable being predicted, we also used a logistic 
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regression model to predict SNP genotype as the outcome. The difference between the 
observed and expected age of onset (CAG-based) was the main predictor of allele 
frequency. Results from this logistic regression were consistent with the results from the 
above described analysis. The adjustment for expected age of onset produced estimates of 
the odds ratio. The odds of having the (A) variant decreased by a factor of 0.929 per year 
increase in observed age of onset (F=5.75, df=1, P=0.017, two-sided Wald test, 95% CI= 
0.875-0.987). In other words, the (A) variant phased to the wild-type allele was  
associated with an earlier age of onset regardless of CAG-repeat length. Our result thus 
suggests that the rs13102260 (A) variant is a genetic risk variant that accelerates AO in 
HD patients when phased to the wild-type HTT allele. 
It should be noted that we do not have access to additional HD patient data of 
comparable sample size that are also enhanced by family-based designs or oversampling 
extreme-phenotype cases. We did attempt a third association study of a random 
population sample obtained from the EHDN Registry (n=26 (G/A); n=418 (G/G)) for 
which we did not observe a significant association between age of onset and the presence 
of the rs13102260 (A) variant on the wild-type allele (t=0.58, 324 df, P=0.56) 
(Supplementary Fig. 4). To our knowledge, no other HD patient population except the 
Danish cohort has been described to display a high frequency of the rs13102260 (A) 
variant phased to the HD disease allele. We observed an enrichment of (A) variant 
carriers with extremely early AO in the UBC population: 41% (9/22) of the HD subjects 
that displayed extremely early AO (<15
th 
percentile) also carried the (A) variant (Fig. 5c), 
whereas 15% (4/26) of the subjects displaying an extremely early AO carried the (A) in 
the random EHDN Registry population of a similar size (Supplementary Fig. 4). 
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Genotyping familial cases in the Danish cohort also reflected enrichment effects with 
26% (9/35) of the (A) variant carriers on the HD disease allele displaying extremely late 
age of onset (>85th percentile) compared to 9% (40/432) in the (G/G) carriers (Fig. 5c). 
 
 
Estimation of rs13102260 (A) variant disease modifier effects on HD disease allele 
 
Association analysis of the UBC cohort showed that HD subjects with the rs13102260 
(A) variant displayed on average 3.9 years earlier age of onset compared to HD subjects 
with the (G) variant phased to the wild-type allele (Fig. 5b). In contrast to the UBC 
cohort, the relationship between CAG-repeat size and expected age of onset was non- 
linear for the Danish cohort as described (P=0.019) (Supplementary Fig. 6). This effect 
increased by 0.47 years per year of increased expected onset age (t=2.41, 73.9 df, 
P<0.05). The estimated disease-modifying effect of the (A) variant phased to the HD 
disease allele was greater in HD subjects with shorter CAG repeat lengths (Table 1). For 
example, (G/A) heterozygotes with CAG repeat lengths of 41 presented age of onset on 
average 17.3 years later than expected (extrapolation with no data for (G/A) 
heterozygotes), while (G/A) heterozygotes with CAG repeat lengths of 55, presented age 
of onset in average 2.7 years later. (G/A) heterozygotes with CAG repeat lengths of 43, 
which represent the shortest CAG-length with relevant data, presented a delayed AO with 
on average 13.1 years compared to (G/G) homozygotes. Here, to further show the effect 
of rs13102260 on age of onset, we calculated the ratio AO (=observed AO/expected 
AO)
8
. Compared to the (G/G) homozygotes, HD subjects with the (A) variant phased to 
the wild-type allele showed lower ratio AO values, while HD subjects with the (A) 
variant phased to the HD disease allele showed higher ratio AO values (Fig. 5d). 
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rs13102260 (A) variant correlates with distinct haplotype pattern 
 
We next performed sequence analysis of the 22 (G/A) carriers analyzed in the UBC 
cohort. Interestingly, sequencing confirmed two distinct haplotype patterns correlating 
with the rs13102260 (A) variant including the 6bp repeat VNTR in the HTT gene 
promoter and the polymorphic CCG region in exon 1, which have been previously 
reported
36,38-40
. Of all the HD subjects with the (A) variant on the wild-type allele, 55% 
(12/22) carried the two-repeat allele at the 6bp VNTR loci in conjunction with 
(CCG)7(CCT)3 at the CCG polymorphic region (alternately referred to as CCG8) 
(Supplementary Table 4) (Supplementary Fig. 5). Forty-five percent (10/22) carried the 
one-repeat allele of the 6bp VNTR locus in conjunction with (CCG)7(CCT)2 at the CCG 
polymorphic region (alternatively referred to as CCG7). Previous studies showed that the 
copy number at the 6bp VNTR loci in itself did not affect transcriptional activity
17
. 
Remarkably, the haplotype carrying the rs13102260 (A) variant, the two-repeat alleles at 
the 6bp VNTR loci and CCG8 on the wild-type HTT allele that was represented in the 
(G/A) heterozygotes in the UBC cohort that associated with earlier AO, corresponded to 
the haplotype on HD disease alleles in the Danish HD families that we previously 
reported to be associated with delayed AO
36
. 
Genotype at rs13102260 regulates allele-specific expression of HTT protein 
 
Finally, we assessed whether the genetic variation at rs13102260 modulates protein levels 
in HD patient fibroblast lines. We compared HD patient fibroblast lines with different 
genotypes at rs13102260: homozygous (G/G), heterozygous with (A) variant phased to 
the wild-type allele or heterozygous with (A) variant phased to the HD disease allele, 
respectively. The (A) variant significantly down-regulated HTT protein levels when 
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phased to the wild-type allele (t(3)=3.27, P<0.05) (Fig. 6a). The HTT levels were reduced 
by approximately 50%, which corresponds to the reduction observed in transcriptional 
activity (Fig. 1h). As expected, the (A) variant also significantly down-regulated mutant 
HTT (mHTT) protein levels when phased to the HD disease allele (~25% decrease, 
t(3)=2.46, P<0.05) (Fig. 6a). We observed a general reduction of mHTT protein levels 
compared to the wild-type protein regardless of genotype. This allele-specific expression 
difference might be explained by intrinsic tissue-specific effects, epigenetic modifications 
or HD haplotypes that might contain cis-regulatory elements influencing gene regulation. 
Thus, we showed that the (A) variant is a modifier of protein levels; the (A) variant 
phased to the wild-type allele significantly reduced wild-type HTT protein levels, while 
the (A) variant phased to the HD disease allele reduced the levels of mHTT protein. 
These results revealed functional consequences of this cis-acting regulatory variant that 
altered NF-B binding, reduced HTT protein levels and associated with modulation of 
age of onset in HD patients (Fig. 6b). 
 
DISCUSSION 
 
Genetic disease modifiers cause single gene diseases such as HD to display features of 
complex traits, by influencing the disease expressivity
41,42
. We here identify a cis-acting 
regulatory variant in the HTT promoter that acts in an allele-dependent manner as a 
bidirectional genetic modifier in HD. We show that the identified rs13102260 (G/A) SNP 
decreases NF-B binding to the HTT promoter resulting in reduced HTT expression and 
exerting allele-specific modifier effects on age of onset in HD patients. 
To put our results into clinical context, patients with the (A) variant phased to the 
HD disease allele develop motor symptoms on average 10 years later compared to HD 
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patients with the (G) sequence variant. Interestingly, the estimated disease-modifying 
effect was greater in HD subjects with shorter CAG repeat lengths and declined with 
increased CAG repeat length (Table 1). In contrast, we further show in an independent 
cohort that patients with the (A) variant on the wild-type allele are estimated to develop 
HD motor symptoms almost 4 years earlier than patients with the (G) variant. SNP 
analysis and genotype association tests thus demonstrated the disease-modulatory effects 
of rs13102260 (G/A) on AO in HD. Biochemical analysis further validated the potency of 
this cis-acting genetic variant by measuring its allelic-specific effects on transcriptional 
activity, binding- and protein expression. 
Several potential trans-acting disease modifiers which influence AO in HD have 
previously been reported
43-47
. Although, none of the reported findings has yet revealed 
the mechanism of action by which it contributes to disease pathogenesis, identification of 
genetic modifiers in HD is important for two reasons: 1) these genes and related 
pathways are excellent potential therapeutic targets in HD; and 2) these may provide 
improved prognostic information for HD gene carriers. 
Genome-wide studies have demonstrated that differential allelic gene expression 
is common i.e. allelic imbalance
48
. Cis-regulatory variants altering gene expression are an 
important potential source of phenotypic difference thought to play an important role in 
the pathogenesis of many complex diseases, but so far none have been identified in HD. 
Recently, a genome-wide study focusing on NF-B (p65) binding sites showed that 
genomic structural variants such as SNPs frequently caused differences in gene 
expression due to altered binding of NF-B49. 
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Although NF-B is nearly ubiquitously expressed, its role in neurons of the 
central nervous system is controversial
50 
(see Supplemental Discussion). We showed that 
NF-B regulation of the HTT promoter was dynamic both using siRNA knockdown of 
NF-B and with cytokine stimulations and inhibitors. Interestingly, we also showed an 
increased NF-B activity in striatum in naïve mouse brain, which is the brain region 
primarily affected in HD. Our overall findings demonstrate that NF-B directly binds to 
and increases the transcriptional activity of the HTT promoter; providing the potential for 
a toxic feed-back loop which could result in a detrimental increase in expression of 
mutant HTT in neurons in the striatum. Given the selective effects of HD pathogenesis in 
the striatum, our finding that NF-B activity is significantly increased in striatum in naïve 
mouse brain suggest that the interplay between NF-B and HTT merits additional 
investigation. We propose NFB to be further investigated as a therapeutic target in HD. 
Expression levels of mutant HTT contribute to neuropathology in HD, most 
probably in combination with an increased sensitivity in specific brain regions
13
. The 
expression levels of mutant Htt modulate both the onset and progression of the HD 
phenotype in the YAC128 mouse model of HD. Increased levels of mutant Htt are 
associated with increased sensitivity to excitotoxicity, earlier AO and more rapid disease 
progression
14
. Importantly, in this mouse model of HD, decreasing the levels of wild-type 
Htt increases the cellular toxicity of mutant Htt
15,16
, and over-expression of wild-type Htt 
ameliorates striatal neuronal atrophy
51
. 
 
Cis- and trans acting factors as well as different environmental exposures alter the 
balance of gene expression, and ultimately affect disease expressivity in HD patients
41,42
. 
Recent studies suggest allelic imbalance with mutant HTT mRNA more abundant 
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compared to the wild-type mRNA in post-mortem HD striatum and cortex, while there 
was no difference in the cerebellum
52
. Our human data suggest that reduced levels of 
mHTT delay the onset of HD, providing support for future HTT gene silencing 
therapeutic approaches. Our data also suggest that reduced levels of wild-type HTT may 
accelerate HD onset, although the effect of the rs13102260 genotype appears to be 
smaller. The balance between wild-type and mutant HTT could be thought of as a “yin- 
yang” relationship. We here demonstrated that the cis-acting rs13102260 sequence 
variant potently affects the regulation of the HTT promoter by altering the NF-B binding 
site, suggesting that the sequence (A) variant leads to increased allelic imbalance. 
Calculations on the estimated rSNP effect further suggest that the cis- regulatory (A) 
variant exerts a much greater disease-modifying effect on AO when phased to the HD 
disease allele compared to the wild-type HTT allele. Our in vivo results in HD patients 
thus suggest that reduction of mHTT is a more potent disease modifier of AO than 
reduction of wild-type HTT. HD subjects with CAG repeat lengths of 43 presented AO 
on average 13.1 years later than expected (Table 1). This has implications not only for 
our understanding of the interplay between wild-type and mutant HTT, but more 
importantly for the gene silencing strategies applied in HD. Our results thus highlight the 
importance of continued refinement of our understanding of allelic imbalance in HD 
patients. 
HD is a single gene disorder thought to be mediated by a toxic gain-of-function, 
and silencing of HTT expression is an attractive therapeutic approach. Non-allele-specific 
silencing of both the wild-type and the mutant HTT in HD fibroblast lines resulted in 
increased caspase-3-like activity, while knockdown of only the mutant HTT did not
53
. 
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Studies performed in mice have suggested that non-allele specific silencing alleviates HD 
symptoms
54-56
, while other studies have provided support for allele-specific silencing in 
HD
57-59
. Our results suggest a disadvantage of lower wild-type HTT levels, and as most 
HTT silencing studies have been relatively short-term and performed in mouse, an issue 
of potential concern is whether non-allele specific silencing may have undesirable effects 
by decreasing levels of wild-type HTT. Neuroprotective disease-modifying treatments 
will likely start in young adulthood and continue throughout life. Our study nevertheless 
provides the first clinical evidence that HTT gene silencing therapies for HD will be 
efficacious. If these therapies are non allele-specific, we predict that they will have a net 
beneficial effect, but that allele-specific approaches targeting only mHTT may have 
greater therapeutic efficacy. 
 
Identification of disease-modifying targets and/or mechanisms would be an 
invaluable and long awaited addition for drug development in HD as well as other 
neurodegenerative diseases. In this study, we have identified NF-B as a trans-acting 
factor that regulates HTT gene expression and rs13102260 to act as a bidirectional disease 
modifier. We thus refine the notion of allele-specific relationships between cis-         
acting regulatory elements, the transcriptional rate of HTT expression, and age of onset in 
HD subjects. In conclusion, this study has implications for therapeutic strategies aimed at 
silencing of the HTT gene in HD patients. Genotyping of rs13102260 may further provide 
prognostic information of significance for a subset of HD gene carriers. Continued 
identification of cis- and trans regulatory elements will provide insights into their impact 
on disease expressivity and identify novel targets for disease-modifying therapeutic 
interventions in HD. 
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METHODS 
 
Promoter constructs used in reporter assays 
DNA samples from four HD patients from the Huntington Disease BioBank at the 
University of British Columbia (UBC HD BioBank) were selected that represent a variety 
of different haplotypes observed in HD patients (Supplementary information). All of  
these haplotypes carried the rs13102260 (G) sequence variant. The HD promoter 
fragments were amplified together with the disease causal polymorphic region of exon 1 
to maintain the allelic linkage between the two elements. The PCR products were cloned 
to isolate individual clones of each allele in order to abrogate the possibility of 
monoallelic bias in sequencing. Furthermore, both strands of multiple clones per patient 
were sequenced using overlapping sequence reads to rule out any artefacts from 
amplification. Sequence analysis performed prior to cloning into the reporter constructs 
identified additional PCR-induced single base pair changes generated during the 
amplification process. Three pseudo-alleles displaying PCR-induced sequence changes 
were included in our panel to assess their potential effects on transcriptional activity 
(constructs 3, 5 and 8 were derived from parent constructs 2, 4 and 9, respectively). 
Human HD patient DNA was PCR-amplified using the following primers: forward 5’ 
CTC AGA GAC ACC ATG CCAGA 3’; reverse 5’AGC CCT CTT CCC TCT CAG AC 
3’. The PCR-amplified DNA was sub-cloned using the TOPO® XL PCR cloning kit 
(Invitrogen). PCR amplification of the CAG tract was used to determine if the clones 
originated from the wild-type or the CAG expanded allele. TOPO PCR vector plasmid 
was digested with NcoI (NEB) and fragments were purified before ligating DNA into the 
pGL3-basic promoterless luciferase reporter gene vector (Promega). Cloned full-length 
HTT promoter constructs were 3742 bp. The following restriction enzymes were used for 
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cloning: fragment A (HindIII-NdeI); fragment B (NdeI-PstI); fragment C (PstI-BstBI). 
Plasmid preparations were carried out using the endotoxin-free Maxi kit (Qiagen). 
Reporter assays 
 
HEK293A and immortalized striatal ST14A cells were used for the reporter assays. Cells 
were seeded onto 96-well white plates corresponding to ~80% confluency. Trans-LT1 
transfection reagent (Mirus Inc.) was used to co-transfect the HTT promoter reporter 
constructs, the renilla vector (internal reference control) and pGL3 vector to a total DNA 
amount of 200 ng per well 24 hours post seeding of cells. The results are presented as 
experimental sample ratio where firefly luciferase activity is normalized to Renilla 
luciferase activity as expressed in relative light units (RLU). Negative control wells 
constituted empty pGL3 vector and renilla plasmid. Constructs and the constructs with 
changed TFBS were assayed in three and six wells, respectively. Cells were treated with 
the luciferase substrate reagents 24 hours post transfection (Dual-luciferase assay, 
Promega). The results are presented as experimental sample ratio where firefly luciferase 
activity is normalized to Renilla luciferase activity and is expressed in RLU. TNFwas 
added to the cells six hours after transfection to a final concentration of 20 ng/ml where 
indicated. CAPE (TOCRIS bioscience) was diluted to different concentrations: 2.5ng/l, 
10ng/l, and 20ng/l and fixed volumes (1l) were added two hours prior to stimulation 
with TNF(eBioscience). 
In silico analysis 
 
The cloned DNA sequences were compared to the human build NCBI36, human hg18, 
March 2006 (http://www.ncbi.nlm.nih.gov). Identified sequence variants in the cloned 
constructs affecting the predicted TF binding sites were analyzed implementing a 
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modified version of the RAVEN software analysis (http://www.cisreg.ca/RAVEN). The 
construct sequences were scanned using position weight matrices obtained from the 
JASPAR database of high-quality transcription factor binding profiles 
(http://jaspar.genereg.net/)
60
. The binding site scores for each transcription factor in 
positions overlapping sequence variants were then compared between the two sequences. 
 
The parameters were set to high stringency, requiring binding site profile scores 
exceeding 80% of maximum on at least one of the two constructs. The highest scoring 
predicted TFBS overlapping a sequence variant position was compared to the highest 
scoring predicted TFBS overlapping the same sequence variant position on the other 
allele. TFBS affected by sequence variants were thus defined as any TFBS where the 
relative score of the TFBS profile matrix was at least 80% on either construct 4 or 5 and 
for which the absolute score difference between the binding sites on the two alleles 
exceeded 1.5. 
 
Electrophoretic mobility shift assays (EMSA) 
 
EMSA experiments were performed on nuclear extracts from ST14A cells and 
commercially manufactured biotinylated oligos (IDT). Nuclear extracts were prepared 
according to manufacturer’s protocol (NE-PER® Nuclear and Cytoplasmic Extraction 
reagents, Pierce Thermofisher). Commercially available recombinant p50 was used 
(Promega). EMSAs were performed using double-stranded oligonucleotides spanning 
each putative site. ~30 bp oligonucleotides were designed constituting the respective 
binding sites for CF1/USP, AML-1 and NF-B as described in Supplementary 
information. The forward oligo was biotinylated and duplexed to the unlabeled reverse 
oligo. EMSA reactions were performed according to manufacturer’s protocol 
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(Lightshift® Chemiluminescent EMSA kit, Pierce Thermofisher). ST14A cells were 
stimulated with TNF(eBioscience) (80 ng/ml for 24 hours) for the NF-B gelshift 
assay. 
 
Chromatin immunoprecipitation 
 
ST14A cells were stimulated with TNFα (80 ng/ml) for 24 hours prior to fixation. 
Experiments were performed according to manufacturer’s recommendations (Upstate, 
Millipore). Adult mice (NMR1 strain, 9 months of age; total n=5; male=3, female=2) 
were sacrificed and tissue from striatum, pre-frontal cortex and cerebellum was dissected 
out. Tissue was collected in PBS with protease inhibitors (Diagenode). Tissue samples 
were disrupted with syringe and needle and cells were fixed in 1% formaldehyde in PBS 
for 10 min before addition of glycine to a final concentration of 125 mM. Cells were 
pelleted by centrifugation at 500g for 5 min and washed twice in PBS. For human 
lymphoblastoid cells (LCLs); cells were harvested by centrifugation at 100g for 8 min  
and washed in PBS with protease inhibitors before fixation in 1% formaldehyde for 10 
min followed by addition of glycine to a final concentration of 125 mM. LCLs were 
pelleted by centrifugation and washed twice with PBS. Nuclear extracts were prepared 
from LCL pellets and brain tissue samples following the instructions using the “high 
Cell# ChIP kit” (Diagenode). Chromatin shearing by sonication was performed using a 
Bioruptor UCD 200 (Diagenode). Shearing efficiency and chromatin concentration was 
evaluated after reverse crosslinking and DNA isolation. NFκB antibody (SC-114X, Santa 
Cruz) and control IgG antibody from the High Cell# ChIP kit (Diagenode) was used in all 
ChIP experiments. Results were normalized to 1% input. DNA was analyzed by qPCR on 
the 7500 Fast Real-Time PCR System (Applied Biosystems). Analysis was performed 
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using the 7500 Software V2.0.1 (Applied Biosystems). Data was normalized to input 
DNA. Primers are described in Supplementary information. 
 
Site-directed mutagenesis 
 
PCR was performed using HiFi Taq (Invitrogen) with the construct 4 C plasmid as 
template. Primers used are described in Supplementary information. DpnI was used to 
digest the methylated template leaving only the unmethylated PCR product. Sequence 
analysis was performed to select for the clones with the correct inserted mutation. 
Mutagenized clones were cloned into the pGL3 plasmid and transformed into 
electrocompetent DH5α. 
 
Western blot analysis 
 
Western blotting was performed on protein samples extracted from ST14A cells 
according to manufacturer’s protocol (Thermofisher). ST14A cells were treated with 
either TNFα (eBioscience) (20 ng/ml) for 6 hours, or in combination with CAPE 
(TOCRIS bioscience) (175 ng/ml) that was added 1.5 hours prior to addition of TNFα. 
19µg of total protein was boiled for 5 minutes before being separated on 7.5% acrylamide 
gels, then transferred to Whatman Protran nitrocellulose membranes. Ponceau-staining 
was performed to ensure protein transfer. The membrane was blocked in 5% skim milk in 
TBST for 1 hour at RT, followed by primary antibody incubation at 4 ºC in 2% skim milk 
solution in TBST overnight utilizing a polyclonal antibody raised against a section of the 
NLS region of NFB p50 (SC-114X, Santa Cruz). After washing the membrane, 
secondary incubation was performed with a goat anti-rabbit IgG-HRP antibody (Santa 
Cruz) in 2% skim milk solution in TBST for 1 hour at RT. The membrane was washed 
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again and incubated in SuperSignal West Pico Chemiluminescent Substrate 
(ThermoScientific) for 5 minutes before being exposed to x-ray film. K562 whole cell 
lysate (Santa Cruz) was used as a positive control for the NFB-western blot analysis. 
PARP (9542, Cell signaling) and β-tubulin (G098, abm) antibodies were used as loading 
controls for the nuclear and cytoplasmic fractions, respectively. For HTT protein 
analysis, primary skin fibroblasts were cultured as previously described 
61 
and cell pellets 
were lysed by resuspension in SDP buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% 
 
Igepal, 40 mM B-glycerophosphate, 10 mM NaF, 1X Roche complete protease inhibitor, 
1 mM sodium orthovanadate and 800 mM PMSF) containing 0.1% SDS. Protein samples 
were denatured in LDS sample buffer (Invitrogen) with 100mM DTT and incubated at 
70°C for 10min. Samples were resolved on 10% low-BIS acrylamide gels (200:1 
acrylamide:BIS) with tris-glycine running buffer (25mM Tris, 190mM glycine, 0.1% 
SDS) containing 10.7mM beta-mercaptoethanol added fresh using the BioRad Protean II 
xi Cell system with cooling unit. Gels were run at 160V for 60min through the stack, then 
250V for 16h. Proteins were then transferred to nitrocellulose at 24V for 2h with NuPage 
transfer buffer (Invitrogen). Membranes were blocked with 5% milk in PBS, and then 
blotted for HTT with anti-HTT antibody (Millipore mAb2166) and anti-Myosin (Abcam 
ab24762), which was the loading control used to normalize the data. Proteins were 
detected with IR dye 800CW goat anti-mouse (Rockland 610-131-007) and AlexaFluor 
680 goat anti-rabbit (Molecular Probes A21076) labeled secondary antibodies. The LiCor 
Odyssey Infrared Imaging system was used for signal detection. 
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siRNA transfection 
 
HEK293 cells (Sigma 85120602) were seeded in 12-well plates at 2.5 × 10
5 
cells/well. 
siRNA knock-down experiments were performed according to DharmaFECT 1 (#T- 
2001-02 GE Healthcare) Transfection Reagent manufacturer's protocols. Twenty-four 
hours after seeding, the cells were transiently transfected with control or NFKB-targeted 
siRNA for RELA (Smartpool 5970) and NFKB1 (Smartpool 4790) combined (final 
concentration of 50nM for each siRNA). Cells were collected for quantitative real-time 
PCR analysis (qPCR) after 72h treatment. 
 
Quantitative real time PCR analysis 
 
RNA was isolated from cells using the Qiagen RNeasy mini kit (Qiagen). 1000 ng of 
RNA was used for RT-PCR carried out with the Applied Biosystems High Capacity 
cDNA Reverse Transcription kit (Life Technologies). qPCR was performed with 
Invitrogen’s Fast SYBR® Green Master Mix according to manual (Life Technologies) on 
the 7500 Fast Real-Time PCR System (Applied Biosystems). Absolute quantification was 
used and analysis was performed using the 7500 Software V2.0.1 (Applied Biosystems). 
A normalization factor calculated on ACTB and HPRT1 results was used to normalize the 
data. Primers used are described in Supplementary information. 
 
HD patient materials 
 
The HD patients analyzed in the Danish cohort originated from 36 Danish HD families, 
and have previously been described
36
. The B-haplotype families (n=8) in Denmark are 
likely to be connected via a common ancestor, an HD founder carrying the B-haplotype, 
as their chromosome 4p16.3 haplotypes are similar, and the families all originate from 
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the same geographical area. The HD patients genotyped in the UBC cohort were 
primarily Canadians of European origin obtained from the Hayden lab and the UBC HD 
BioBank (UBC CREB H06-70467 and H05-70532). To enable identification of disease- 
modifying SNP variants, the UBC cohort consisted of samples collected from a single 
member from each family with the most extreme AO phenotype if present as defined by 
the Langbehn et al formula.
8,37 
In families with neither mean nor extreme outliers in 
terms of AO, a single randomly selected family member was used. The EHDN Registry 
cohort represented a random cohort with patient data obtained from sixteen different 
countries in Europe (with multiple sites within each country) with no specific selection 
strategies applied for inclusion. Ethical approval was obtained from the local ethics 
committee for each study site. HD subjects were categorized into percentiles based on 
their ratio AO (observed AO/expected AO); Mean (40-60
th
) percentile (ratio AO=0.93- 
1.05); early 15-40
th 
percentile (ratio AO=0.93-0.83); extremely early <15
th 
percentile 
(ratio AO<0.83); late 60-85
th 
percentile (ratio AO=1.05-1.17); extremely late >85
th 
percentile (ratio AO>1.17. AO reporting procedures differed between the cohorts. The 
EHDN Registry cohort involved historical self-reporting, whereas the same clinicians 
assessed the patients in the UBC and Danish cohorts longitudinally. 
 
 
Exclusion of HD patients in cohort data 
 
In the Danish cohort the total number of genotyped HD subjects were n=98: 36 (G/A) 
carriers with the (A) variant phased to the HD disease allele, three (G/A) carriers with the 
(A) variant phased to the wild-type allele, 53 (G/G) carriers and six (A/A) homozygotes. 
Due to the very low number the three (G/A) heterozygous patients in the Danish cohort 
with the (A) variant phased to the wild-type allele were excluded from analysis. Subjects 
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in the Danish cohort were excluded with CAG repeat lengths of 40 or less (n=6) due to 
clear evidence of biased observation towards those with early onset. Two subjects with 
CAG length 41 and genotype (G/G) were also excluded due to extremely early reported 
age of onset with 22 and 35 years prior to expected onset. This bias is consistent with the 
prior experience of Langbehn et al 
8
. Note that exclusion of these subjects decreases the 
estimated protective effect of the (A) sequence variant when in phase with the HD  
disease allele. Five (G/G) homozygotes with CAG lengths greater than 55 were also 
excluded. They add no evidence to the assessment of the SNP effect, their CAG- 
expected age of onset is not well-established using the same analysis techniques used for 
the CAG range 41-55, and their early onset ages only allows them to serve as potentially 
influential but irrelevant outliers. In the UBC cohort the total number genotyped HD 
subjects were n=459: 26 (G/A) carriers with the (A) variant phased to the wild-type allele, 
2 (G/A) carriers with the (A) variant phased to the HD disease allele and 431 (G/G) 
carriers. In the UBC cohort, four (G/A) heterozygotes and 40 (G/G) homozygotes with 
CAG lengths lesser than 41 or greater than 55 were excluded from primary analysis.   
Two (G/A) subjects with the (A) variant phased on the HD disease allele were also 
excluded from the UBC data analysis. In the EHDN Registry cohort, the total number of 
genotyped HD subjects including all CAG repeat lengths were (n=497): 32 (G/A) carriers 
with the (A) variant phased to the wild-type allele, 459 (G/G) carriers and 6 (G/A) 
carriers with the (A) variant phased to the HD disease allele. In the EHDN Registry 
cohort, six (G/A) heterozygotes with the (A) variant phased on the wild-type allele and 41 
(G/G) homozygotes with CAG lengths lesser than 41 or greater than 55 were excluded 
from primary analysis as well as the six (G/A) heterozygotes with the (A) variant phased 
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on the HD disease allele. There was no evidence for biased ascertainment at CAG repeat 
length 40 in the UBC and the EHDN Registry cohorts. However, for comparability and 
uniformity of analysis, all three data sets i.e the UBC, EHDN Registry and the Danish 
cohorts, were analyzed using the same cutoff of CAG lengths 41-55. Analysis was also 
performed including HD subjects with CAG repeat length 40 in the UBC and the EHDN 
Registry data set with no substantive changes in the results (data not shown). 
 
Statistical analysis of clinical data 
 
For analysis of the clinical human data, we studied the relationship between HD age of 
onset and the presence and phase of the human SNP rs13102260. For the Danish data, we 
fit weighted least square models predicting observed ages of onset as a function of the 
rs13102260 (G/A) genotype, and expected age of onset based on CAG length, as 
estimated by Langbehn et al 
8
. We controlled for a random effect of family pedigree. 
Because variance in age of onset tends to increase with higher expected age of onset 
 
(lower CAG length), we also included a random effect for expected age of onset, 
effectively turning this into a weighted least squares model based on CAG-predicted 
onset age. Analyses were performed using PROC Mixed of SAS 9.3, and the Kenward- 
Rogers procedure was used to estimate residual degrees of freedom. We used similar 
models for the UBC and Registry data, except that all subjects were from separate 
families in the UBC cohort and possible familial relationships were unknown in the 
EHDN Registry cohort. Thus, no random family effect could be used. Because the UBC 
data were collected on the basis of age of onset, with SNP genotype as the unknown 
variable being predicted, we also compared the linear model result to those from the 
corresponding logistic regression predicting SNP genotype as the outcome. The 
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difference between the observed and CAG-based expected onset age was the main 
predictor of allele frequency. For comparability to the mixed linear models, we also 
include expected age of onset as a covariate, though it lacked significance as a predictor 
of rs13102260 (G/A) genotype. 
 
SNP genotyping 
 
The Taqman® SNP Genotyping assay (C_31758132_10) (Applied Biosystems) was used 
for genotyping of the rs13102260 (G>A). TaqMan® Genotyping master mix (Applied 
Biosystems) was used and the reaction was set up according to manufacturer’s 
recommendations. PCR conditions: 95°C for 10 min; 92°C for 15 sec and anneal/extend 
at 62°C for 1 min for 40 cycles using the 7500 Fast Real-Time PCR system (Applied 
Biosystems). Analysis was performed using the 7500 Software V2.0.1 (Applied 
Biosystems). In the Danish cohort the rs13102260 (G/A) genotype was assessed using 
Sanger sequencing using the following primer sequences: Forward 5’- 
GCCTCACCCCATTACAGTCT-3’ and Reverse 5’-GGCAATGAATGGGGCTCT-3’ 
 
Phasing of (G/A) carriers 
 
In the Danish cohort phasing of the rs13102260 (G/A) genotype was done in each HD 
family by segregation of affected and/or unaffected genotypes within the pedigree, similar 
to the procedure applied in the UBC cohort. In the UBC cohort, all HD subjects were  
first genotyped for rs13102260. We then genotyped relatives of the heterozygous (G/A) 
carriers to phase the (A) variant to the wild-type or the HD disease allele. Relatives 
included asymptomatic or unaffected offspring, parents or siblings, or affected distant 
relatives such as cousins, nieces and nephews The unaffected parent was almost 
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exclusively (G/A) and the affected parent was (G/G) (26 out of 28). The (A) variant thus 
segregated with the wild-type allele inherited from the unaffected parent for all the (G/A) 
carriers that were included in the association analysis. For (G/A) carriers in the EHDN 
Registry we used a PCR-based approach for phasing. Human HD patient DNA was PCR- 
amplified using the following primers: forward 5’-ATTACAGTCTCACCACGCCC-3’; 
reverse 5’-GACAAGGGAAGACCCAAGTG-3’. The wild-type and the CAG-expanded 
HD disease alleles were separated by running the PCR product on a 0.7% agarose gel. 
DNA was extracted using a gel extraction kit (Invitrogen) and DNA concentrations were 
determined using the Nanodrop spectrophotometer (ThermoScientific). Capillary 
sequencing (Applied Biosystems) was performed using the same primers as for the initial 
PCR amplification. The obtained sequences incorporated the rs13102260 (G/A) and the 
CAG tract. Sequence Scanner v1.0 (Applied Biosystems) and ApE Plasmid editor 
software were used for sequence analysis. 
 
Statistical analysis of non-clinical data 
 
Student’s unpaired t-test was performed for comparison between two groups (GraphPad 
Prism5). One-way analysis of variance (ANOVA) with Bonferroni’s or Dunnett’s 
multiple comparison tests were used for data analysis of more than two groups 
(GraphPad Prism5). Significant differences were set at *P<0.05, **P<0.01, ***P<0.001. 
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FIGURE LEGENDS 
 
Figure 1 Cis-regulatory SNP in the NFκB binding site alters transcriptional activity 
of the HTT promoter. 
Reporter assays measuring basal transcriptional activity of twelve HTT promoter 
constructs. The transcriptional activity of construct 5 was reduced by (a) 57% (P<0.01, 
two-tailed unpaired t-test) in HEK293A cells and by (b) 51% (P<0.001) in ST14A cells 
compared to its parent construct 4. (c) Cartoon of the HTT promoter regions (A, B, C)  
that were investigated for regulation of expression activity. Construct 4 differed from 
construct 5 at ten sequence positions as indicated (relative to the translation start site). In 
silico analysis identified putative transcriptional factor binding sites (TFBS) potentially 
affected by the sequence variant differences. Genetic variants that overlap with putative 
TFBS were identified. Validated SNPs are indicated with blue triangle. Variants without 
frequency submission are indicated in gray. (d) The proximal promoter fragment C from 
construct 5 reduced transcriptional activity of the construct 4 promoter background, while 
the construct 4 fragment C rescued the transcriptional activity of construct 5 (P<0.001). 
(e) The 5 C fragment alone was sufficient for the reduced transcriptional activity 
(P<0.001). (f) Sequence variation in the NF-κB TFBS caused the reduced transcriptional 
activity observed in the construct 5 full-length and fragment C constructs (P<0.001). (g) 
TFBS motifs and respective construct 4 and 5 sequence variants. The identified NFκB 
TFBS in the HTT promoter comprises the rs13102260 (G>A). (h) Site-directed 
mutagenesis changing GA in the first position of the NF-κB TFBS in construct 4 C 
reduced transcriptional activity to similar levels as observed for the construct 5 full- 
length and C-fragment (P<0.001). Each construct was assayed in triplicate. The data is 
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pooled from two independent experiments (mean ± SEM, n=6) (One-way ANOVA with 
with Bonferroni’s multiple comparison test was used in (d) and Dunnett’s multiple 
comparison test was used in (e-h). 
 
Figure 2 NF-B binds to the huntingtin promoter in vitro and in vivo 
 
(a-c) ChIP on different brain regions of naïve mice was used to investigate whether NF- 
B bound the site in vivo. The mouse Htt promoter constitutes three putative NF-B 
TFBS within 1000 bp upstream of the translation initiation codon. There was a NF-B 
enrichment at all analyzed TFBS regions comparable to the positive control region for 
IL6 as assessed by qPCR (Striatum F(7,32)=1.75, P=0.133; Prefrontal cortex 
F(7,32)=2.44, P<0.05, Cerebellum F(7,32)=7.22, P<0.001, one-way ANOVA) (mean ± 
SEM, n=5). (d) There were significant increases in NF-B recruitment in striatum 
compared to pre-frontal cortex and cerebellum at TFBS2 (Tissue F(2,96)=5.53, P<0.01, 
TFBS F(7,96)=3.15, P<0.01, interaction (F(14,96)=4.28, P=0.311, two-way ANOVA). 
(e) To study the NF-B occupancy at the HTT promoter in a human context, ChIP 
analysis was performed in lymphoblastoid cell lines (LCL) derived from HD patients. 
There was an increased enrichment of NF-B at the predicted NF-B TFBS containing the 
rs13102260 in human LCLs (F(3,32)=4,28, P<0.05, one-way ANOVA with Dunnett’s 
test) compared to a control region upstream in the HTT promoter region containing two 
putative NF-B TFBS (-2065; -2011bp upstream from translation start site) (mean ± 
SEM, n=9). (f) Rat striatal ST14A cells stimulated with TNFα were assessed. Four 
putative NF-B TFBS were identified in the rat Htt promoter within 1000 bp upstream of 
the translation initiation codon (TFBS1 containing two predicted binding sites). We 
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observed an enrichment of NF-B for all three regions comparable to what was observed 
for the IL6 promoter (F(7,16)=5.09, P<0.01, one-way ANOVA with Bonferroni’s test) 
(mean ± SEM, n=3). Immunoprecipitation with a normal mouse IgG antibody was used 
as a negative control. 
 
Figure 3 Cis-regulatory variants in the HTT promoter alter NF-κB binding 
 
(a,b) Electromobility shift asays (EMSA) were performed to assess the binding of NF-κB 
to the putative NF-κB TFBS identified in constructs 4 and 5. Binding of nuclear extracts 
from TNFα-stimulated ST14A cells and recombinant NF-κB p50 protein were tested. 
NF-κB bound stronger to the allele 4 compared to the allele 5 oligonucleotide in a 
concentration-dependent manner. EMSA showed that NF-B binding to the 
oligonucleotide containing the rs13102260 (A) variant was fully abolished, as assessed 
with both (c) ST14A nuclear extract and (d) recombinant NF-B p50 protein. Lanes 1-2, 
no nuclear extract; lanes 3, 5, 7, allele 4 oligonucleotide and lanes 4, 6, 8, allele 5 
oligonucleotide incubated with ST14A nuclear extract or recombinant NF-κB p50, 
respectively; lanes 9-10, unlabeled competitor oligonucleotide added to labeled 
oligonucleotide + protein extract. (gsu=gel shift units). 
 
Figure 4 Targeting of NF-κB modulates HTT expression 
 
(a) siRNA knock-down of NF-B in HEK293 cells. Down-regulation of NFKB1 (specific 
for p105, precursor to the p50 subunit) and p65 mRNA levels, decreased the levels of 
HTT mRNA expression as measured by qPCR (t(6)=3.53, P<0.01) (mean ± SEM, n=7). 
siRNA knockdown efficiency was on average 83% for NFKB1 (t(16.8), p<0.0001) and 
70% for p65 (t(6)=7.95, P<0.0001). (b) ST14A cells expressing constructs 4 or 5 were 
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stimulated with TNFα. The TNFα-stimulation resulted in increased transcriptional activity 
of construct 4 compared to the untreated control (F(3,8)=29.7, P<0.001, one-way 
ANOVA with Dunnett’s test). No increase in transcriptional activity was detected for 
construct 5 upon TNFα-stimulation. (c) CAPE treatment of ST14A cells expressing 
construct 4 reduced the TNFα-induced increase in transcriptional activity in a dose- 
dependent manner by inhibition of NFκB activity (F(4,7)=6.24, P<0.05, one-way 
ANOVA with Dunnett’s test). One representative data set out of three independent 
reporter assay experiments is shown for each panel (mean ± SEM). (d) TNFα-stimulation 
of the ST14A cells resulted in increased protein levels of NFκB subunits as measured by 
western blot analysis. The p50 subunit increased the most in the nuclear fraction 
following TNFα-stimulation of ST14A cells. The p65 (65 kDa), RelB (68 kDa) and c-Rel 
(69 kDa) were also increased, but not to the same extent as p50. The cytoplasmic fraction 
showed strong bands for the precursor subunits p100/p105, in addition to bands for the 
p50 subunit, which were expressed at similar levels across the different treatments. CAPE 
treatment had no effect on expression of the NF-κB protein. PARP and β-tubulin show 
equal loading of protein across lanes for the nuclear and cytoplasmic fractions, 
respectively. 
 
Figure 5 rs13102260 (A) variant alters NF-κB binding and modulates HD age of 
onset. (a) Familial HD cases from Denmark were genotyped for the rs13102260. 
Presence of the rs13102260 (A) variant on the HD disease allele had a clear association 
with later age of HD onset (35 of 82 HD subjects were (G/A) heterozygotes) (t=5.08, 
27.1 df, P<0.0001). (b) HD patients from the UBC BioBank cohort were genotyped for 
the rs13102260 (G/A). Presence of the rs13102260 (A) variant on the wild-type allele 
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was associated with an earlier age of HD onset (22 of 413 HD subjects were (G/A) 
heterozygotes) (P= t=-2.57, df=367, P=0.010). (c) HD cases (Danish and UBC cohorts) 
were categorized according to the AO percentile, given their expected AO and the 
observed AO. A higher proportion of early AO cases was observed in (G/A) carriers with 
the (A) variant phased to wild-type allele (64%, of which 41% displayed extremely early 
AO below <15
th 
percentile) compared to the (G/G) (41%, of which 21% displayed 
extremely early AO below <15
th 
percentile), while a higher proportion of late AO cases 
was observed in (G/A) carriers (63%, of which 26% displayed extremely late AO above 
>85
th 
percentile) with the (A) variant phased to the HD disease allele compared to (G/G) 
carriers (24%, of which 9% displayed extremely late AO above >85
th 
percentile). (d) ratio 
AO (=observed AO/expected AO) showed the effect of rs13102260 on age of onset. HD 
subjects with the rs13102260 (A) variant phased to the wild-type allele showed lower 
ratio AO values, while HD subjects with the (A) variant phased to the HD disease allele 
showed higher ratio AO values, compared to the (G/G) carriers ((A) variant phased to 
wild-type allele n=22; (A) variant phased to the HD disease allele n=35; (G/G) carriers 
 
n=432). 
 
 
Figure 6 Genotype at rs13102260 drives allele-specific expression of HTT and 
modulates HD age of onset 
(a) The effect of the rs13102260 (A) variant on wild-type and mutant HTT (mHTT) 
protein expression levels was measured with western blot analysis in HD patient 
fibroblast lines. Wild-type HTT protein was reduced in the samples with the (A) variant 
phased to the wild-type allele compared to the (G) variant (G[WT] vs A[WT]) (t(3)=3.27, 
P<0.05, two-tailed unpaired t-test). Mutant HTT protein was reduced in the samples with 
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(A) phased on the HD disease allele compared to the (G) variant (G[HD] vs A[HD]) 
(t(3)=2.46, P<0.05). The data represents two different fibroblast lines per genotype group 
including two pellets per cell line (mean ± SEM, n=4). Alleles carrying the rs13102260 
(A) variant are labelled in red; (G) variant carriers are indicated in white. For each 
genotype group, the left bar indicates wild-type HTT levels, and the right bar indicates 
mHTT levels. (b) Model for rSNP rs13102260 (G/A) as a bidirectional genetic modifier 
of HD age of onset. rSNP rs13102260 (G/A) is located in the identified NF-B TFBS in 
the HTT promoter immediately proximal to the 5’UTR of the HTT gene. The rs13102260 
(A) variant impairs NF-B binding, reduces transcriptional activity of the HTT gene and 
HTT protein levels. Presence of the rs13102260 (A) variant on the wild-type allele was 
associated with reduced wild-type HTT protein levels and earlier AO, while the (A) 
variant on the HD disease allele was associated with lower mutant HTT protein levels 
and delayed AO in HD patients. 
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Table 1 
Estimation of rs13102260 genotype effects on AO in HD subjects with (A) variant 
phased to HD disease allele 
CAG Exp Model prediction Model prediction SD of SNP effect 
length AO
1
 (A)-HD allele- (A)-HD allele- ExpAO
1
 in years 
HD  ABSENT2 PRESENT3 (A)-HD (A)-HD 
allele    allele4 allele5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
Expected age of onset (Exp AO) calculated as defined by Langbehn et al. 2004 
2
Estimated AO based on model for rs13102260 (G) variant phased to HD disease allele. 
3
Estimated AO based on model for rs13102260 (A) variant phased to HD disease allele. 
4
Increase in standard deviation (SD) when rs13102260 (A) variant phased to HD disease allele. 
5
Estimated number of years delayed onset with rs13102260 (A) variant phased to HD disease 
allele. 
41 57.0 51.4 68.6 1.7 17.3 
42 52.2 47.0 62.0 1.6 15.0 
43 48.1 43.2 56.3 1.5 13.1 
44 44.5 39.9 51.3 1.4 11.3 
45 41.3 37.1 46.9 1.3 9.9 
46 38.6 34.6 43.1 1.2 8.6 
47 36.3 32.5 40.0 1.1 7.5 
48 34.3 30.7 37.2 0.99 6.5 
49 32.6 29.1 34.8 0.89 5.7 
50 31.1 27.7 32.7 0.79 5.0 
51 29.8 26.5 30.9 0.71 4.4 
52 28.7 25.5 29.4 0.63 3.9 
53 27.7 24.6 28.0 0.56 3.4 
54 26.9 23.9 26.9 0.49 3.0 
55 26.1 23.2 25.9 0.44 2.7 
 
